Astera Labs (ALAB) Cash & Equivalents (2023 - 2026)

Astera Labs (ALAB) has reported Cash & Equivalents for 4 consecutive years, with $111.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 31.34% year-over-year to $111.5 million; the trailing twelve-month figure through Jun 2026 stood at $111.5 million (down 31.34% YoY), and the FY2025 full-year result was $167.6 million, up 110.7% from the prior year.
• Cash & Equivalents declined to $111.5 million in Q2 2026 per ALAB's latest filing, from $148.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $696.1 million in Q1 2024 and bottomed at $45.1 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $198.6 million across 4 years, with a median of $140.4 million in 2025.
• The widest YoY moves for Cash & Equivalents: up 110.7% in 2025, down 87.58% in 2025.
• Over 4 years, Cash & Equivalents stood at $45.1 million in 2023, then soared by 76.4% to $79.6 million in 2024, then jumped by 110.7% to $167.6 million in 2025, then sank by 33.5% to $111.5 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $111.5 million, $148.3 million, and $167.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.